EFG Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

EFG Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-8,856	Closed	-$603K	–	197
2024 Q1	$603K	Sell	8,856 -65,422	-88%	-$4.68M	0.1%	187
2023 Q4	$4.65M	Sell	74,278 -8,394	-10%	-$464K	0.88%	23
2023 Q3	$3.75M	Buy	82,672 +7,687	+10%	+$397K	0.89%	36
2023 Q2	$4.21M	Sell	74,985 -20,129	-21%	-$1.14M	0.9%	41
2023 Q1	$4.3M	Buy	95,114 +767	+0.8%	+$37.3K	0.95%	37
2022 Q4	$3.81M	Buy	94,347 +9,991	+12%	+$530K	0.85%	38
2022 Q3	$5.52M	Buy	84,356 +4,456	+6%	+$323K	1.27%	18
2022 Q2	$4.86M	Buy	79,900 +3,840	+5%	+$226K	1.02%	32
2022 Q1	$4.78M	Buy	+76,060	New	+$4.78M	0.72%	48

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

EFG Asset Management's CRSP Position: Q2 2024 in Review

EFG Asset Management sold out of CRISPR Therapeutics (CRSP) in Q2 2024, closing a stake of 8,856 shares — an estimated $603K sold.

EFG Asset Management first reported a position in CRSP in Q1 2022 and held it in 9 quarters. The position peaked at $5.52M in Q3 2022. 449 funds tracked by Wall St. Rank hold CRSP as of Q2 2024.

EFG Asset Management reported no remaining CRISPR Therapeutics position as of Q2 2024 after selling out during the quarter.
EFG Asset Management sold 8,856 CRISPR Therapeutics shares in Q2 2024, an estimated $603K.
EFG Asset Management first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 9 quarters.
EFG Asset Management's CRISPR Therapeutics position peaked at $5.52M in Q3 2022.
449 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2024.

Based on EFG Asset Management's 13F filing for Q2 2024, filed 25 Jul 2024.